Background and Aim: Some single-nucleotide polymorphisms (SNPs) are associated with the development of non-alcoholic fatty liver disease (NAFLD). As one of the genetic factors, PNPLA3 rs738409 (I148M) is important to associate with pathogenesis of NAFLD. Because other SNPs remain unclear in Japan, we performed a high-throughput sequencing that targeted more than 1000 genes to identify a novel genetic variant in Japanese patients with NAFLD. Methods: The present study in 36 NAFLD patients and 27 healthy volunteers was performed. A high-throughput sequencer was used to detect the gene variations. Candidate genes were validated by TaqMan SNP genotyping assay in 53 NAFLD patients and 41 healthy volunteers. To investigate the function of candidate gene, we performed biochemical analyses in cultured hepatocytes and liver tissues. Results: EXO1 rs1047840, PTPRD rs35929428, IFNAR2 rs2229207, CPOX rs1131857, IL23R rs1884444, IL10RA rs2228055, and FAM3B rs111988437 were identified as candidate genetic variants, and PTPRD rs35929428 was only extracted as a SNP predicting to cause protein dysfunction. In validation analysis, PTPRD rs35929428 associated with the development of NAFLD (P = 0.015, odds ratio = 5.00, 95% confidence interval: 1.33-18.70). In addition, PTPRD rs35929428 was associated with Fib-4 index and with hepatic fat droplets. Biochemical analyses indicated that PTPRD rs35929428 promoted dephosphorylation of tyrosine 705 signal transducer and activator of transcription 3 (Tyr 705) in hepatocytes. Conclusion: PTPRD rs35929428 was a novel SNP in patients with NAFLD. Through exacerbation of the dephosphorylation of signal transducer and activator of transcription 3 (Tyr 705) in hepatocytes, PTPRD rs35929428 might play a role in hepatic lipid accumulation and fibrosis, followed by the development of NAFLD.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. 1, 2 NAFLD starts with hepatosteatosis and can progress to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). 1, 2 In the process of the development of NAFLD, fat droplets accumulated, inflammation, and fibrosis were induced by several hits, which were dysregulation of adipocytokine, 3 lipotoxicity, 4 Toll-like receptors, 5 gut microbiota, 6 and iron overload. 7 While the etiology of NAFLD has not been completely understood, the development of NAFLD has been strongly related to energy homeostasis and genetic predisposition. 8 Genome-wide association studies have recently identified a number of loci conferring risk for NAFLD. Among these, the rs738409 C > G (I148M) variant of the patatin-like phospholipase domaincontaining 3 (PNPLA3) gene is the most well-validated association, influencing degree of steatosis, grade of inflammation, stage of fibrosis, and risk of HCC 9,11 also in Japan. Especially, this single-nucleotide polymorphism (SNP) was strongly associated with Matteoni type 4 NAFLD, suggesting a useful marker associated with hepatic fibrosis. 12 However, the detailed mechanism underlying this genetic association remains incompletely understood, 10 thereby less contribution for elucidating the pathogenesis of NAFLD. As well as PNPLA3, several SNPs associated with progression of NAFLD are reported. 13 On the other hand, the genetic determinant predisposition except for PNPLA3 remains unclear in Japan. The present study aimed to identify a novel genetic variant in Japanese patients with NAFLD using a high-throughput sequencing that targeted more than 1000 genes and to clarify a possible mechanism on how the genetic variant involved in the pathogenesis of NAFLD.
Material and methods
Subjects and clinical diagnosis. This study was approved by the Institutional Review Board of Asahikawa Medical University. Written informed consent was obtained from all enrolled patients, all of whom were Japanese. NAFLD patients and healthy volunteers (HVs) were recruited from December 2012 to July 2014 at Asahikawa Medical University and Japanese Red Cross Asahikawa Hospital as an estimation group. The NAFLD diagnosis was according to the guideline defined by the Japanese clinical practice guidelines. 14 The methods of collecting HVs were as follows: (i) no history for hepatitis B virus (HBV), hepatitis C virus (HCV), fatty liver, and other liver diseases; (ii) no history of liver dysfunction; and (iii) no history of alcohol abuse and obesity. Physical examination; ultrasound screening; medical history review; questionnaire-based survey for diet, smoking and alcohol intake; and biochemical laboratory tests were performed. Fib-4 index was calculated. 15 Cases with known causes of steatosis, for example, heavy alcohol intake (>20 g/day) and use of medications/herbals known to contribute to hepatic steatosis, were excluded. The subjects with HBV were included if hepatitis B surface (HBs) antigen was positive or HBV DNA positive even if HBs antigen was negative when the level of hepatitis B core (HBc) antibody was high. All patients tested in this study were HBs antigen negative. HBc antibody was positive in 11 patients. Among them, one patient had high level of HBc antibody. However, HBV DNA was negative in the patient. The subjects with HCV were included if HCV antibody was positive or HCV RNA was positive. If HCV antibody was low level, the level of HCV RNA was elucidated. The level of HCV antibody was low in one patient. However, HCV RNA was negative in the patient. Patients with high likelihood to have other known liver diseases including autoimmune disease and primary biliary cirrhosis based on aforementioned information were also excluded.
Primer design for custom amplicon sequencing. We designed multiple primer sets that targeted the exons of 1031 genes (total of 12609 amplicons) using the Ion AmpliSeq Designer software program (https://www.ampliseq.com/browse.action) (Life Technologies, Carlsbad, CA, USA), and these primer sets were provided as five primer pools. These genes were mainly involved in inflammation, energy metabolism, carcinogenesis, and metal metabolism/transport described in our recent publication that examined the autoimmune pancreatitis susceptibility in Japanese peoples. 16 The 12609 amplicons and the targeted lesions are described. 16 Sample preparation for amplicon sequencing. Peripheral blood samples were processed for mononuclear cell isolation by Ficoll gradient centrifugation. The genomic DNA was then extracted and purified using DNeasy Blood & Tissue Kits (Qiagen, Venlo, the Netherlands). The DNA concentrations were determined by a QubitTM Fluorometer (Life Technologies). The quality of the genomic DNA was assessed by agarose gel electrophoresis.
Data analysis for gene variations. All sequencing data were mapped on a human reference genome sequence (GRCh37/ hg19) using the Torrent Suite Software program (Life technologies). The gene variants were then detected by a Torrent Variant Caller plug-in for the software program (Life technologies). The variant information for each sample was imported into the CLC Genomics Workbench software system (CLC bio, Aarhus, Denmark), and Fisher's exact test was performed to determine the significance of the differences among samples. DNA sequencing was performed according to the previous study. 16 TaqMan single-nucleotide polymorphism genotyping assay. The SNP genotyping in each DNA samples was evaluated by TaqMan SNP genotyping assay in the estimation group. By using TaqMan probes identified, EXO1 rs1047840, IL23R rs1884444, CPOX rs1131857, IL10RA rs2228055, PTPRD rs35929428, IFNAR2 rs2229207, and FAM3B rs111988437, quantitative real-time polymerase chain reaction (7300 Real-time PCR system; Applied Biosystems, Foster City, CA USA) was performed for evaluating SNP genotype according to TaqMan SNP genotyping assay protocol.
Validation analysis by TaqMan single-nucleotide polymorphism genotyping assay. As a validation group, 17 NAFLD patients and 14 HVs were added to the estimation group. In total, 53 NAFLD patients and 41 HVs were analyzed in the validation group. In the validation group, the candidate gene that was identified in the estimation group was evaluated by TaqMan SNP genotyping assay.
Histopathological evaluation and immunohistochemistry. The biopsy specimens stained with hematoxylin and eosin were evaluated by the classification of Matteoni 17 and Brunt. 18 The degree of steatosis was evaluated by the following amount of fat droplets as observed under the microscope: 0, <5%; 1, <10%; 2, <34%; 3, <67%; and 4, >67%.
12 Immunohistochemistry was performed by rabbit polyclonal anti-PTPRD (GeneTex, Irvine, CA, USA) and rabbit monoclonal anti-phospho signal transducer and activator of transcription 3 (pSTAT3) (Tyr 705) (Cell Signaling Technology, Danvers, MA, USA). As a secondary antibody, anti-rabbit IgG horseradish peroxidase-conjugated (R&D Systems Minneapolis, MN, USA) was used. PTPRD and pSTAT3 positive cells were analyzed by ImageJ software.
Transfection of PTPRD R995C and interleukin-6 treatment. We incorporated the cDNA that encoded human wild-type PTPRD or PTPRD R995C in gene expression vector pBApo-CMV Pur (Takara, Tokyo, Japan). These vectors were transfected by Lipofectamine 3000 (Thermo Fisher Scientific, Rockford, IL, USA) to Huh7 cells that were derived from Japanese hepatocellular carcinoma and expressed PTPRD detected by TaqMan probe (data not shown), and then we established stable expression cell strain by treatment with puromycin. Therefore, treatment with puromycin can select Huh7, which transfected wild-type PTPRD or PTPRD R995C. Recombinant interleukin-6 (IL-6) (0.5 ng/mL) was added to the medium. After 3 h, protein was extracted by RIPA buffer.
Western blotting analysis. Protein expression of STAT3 and pSTAT3 (Tyr 705) in the Huh7 cells was investigated by western blotting. Proteins were reacted overnight at 4°C with rabbit monoclonal anti-STAT3 (Cell Signaling Technology), rabbit monoclonal anti-pSTAT3 (Tyr 705) (Cell Signaling Technology) or actin (BD Biosciences, San Jose, CA, USA) and reacted with secondary antibody horseradish peroxidase-conjugated anti-rabbit IgG and antimouse IgG (R&D systems) for 1 h.
Statistical analysis. In the amplicon sequencing analysis, the candidate gene variations were filtered using the P-values from Fisher's test. The candidate genes with both of the P-values of <0.05 accompanying amino acid substitution were selected. The results of sequencing analysis and TaqMan SNP assay were compared by Cohen's kappa. Cohen's kappa >0.8 were considered to be reliable as regards the diagnosis by two methods. 19 Other dates are expressed as median and ranges. Mann-Whitney U-test or Fisher's exact test was used in two groups, and analysis of variance was used in more than two groups. P-values of <0.05 were considered statistically significant.
Results
Characteristic of enrolled patients with non-alcoholic fatty liver disease and healthy volunteers in the estimation group. A total of 63 participants, that is, 36 patients with NAFLD and 27 HVs, as the estimation group were enrolled in this study. In the 36 patients, 16 patients were male and 20 were female and the median age was 60.5 years (range, 28-80). Among them, 23 patients underwent liver biopsy and five patients were diagnosed with liver cirrhosis. Moreover, 10 and 7 patients had Matteoni type 3 and 4 NAFLD, respectively. In the 27 HVs, the median age was 29.0 years (range, 20-49). The age in the HVs was significantly younger than that in the patients with NAFLD (P < 0.01), while the gender ratio was not significantly different between the two groups.
Identification of genetic variations in patients with non-alcoholic fatty liver disease. We first profiled the difference of genetic variant frequencies between the patients with NAFLD and the HVs. Then seven SNPs were extracted by Fishers' exact test when P-values less than 0.05 accompanied by amino acid substitution were regarded as significant candidate genes (Table 1) (Table 1) . Finally, we predicted by PROVEAN prediction (http://provean.jcvi.org/index.php) 20 whether amino acid substitution by these four SNPs had an effect on the protein function. Then receptor-type tyrosine-protein phosphatase delta (PTPRD) rs35929428 (R995C) was only extracted as an SNP predicting to cause a protein dysfunction.
Validation of PTPRD rs35929428 by TaqMan single-nucleotide polymorphism genotyping assay. Next, in 53 NAFLD patients and 41 HVs as the validation group, we analyzed the validation of PTPRD rs35929428 by TaqMan SNP genotyping assay. Clinical characteristics in 53 patients are shown in Table 2 . Liver biopsy was performed in 29 of 53 patients, and seven patients were diagnosed with liver cirrhosis. As well as the results of highthroughput sequencing, the ratio of PTPRD rs35929428 GA was significantly higher in NAFLD patients than in HVs by TaqMan SNP genotyping assay (Fig. 1) .
The association of PTPRD rs35929428 with hepatic fibrosis and fat accumulation. Table 2 shows the clinical characteristics of 38 PTPRD rs35929428 GG and 15 PTPRD rs35929428 GA patients. Between the two groups, there were no significant differences in age, sex, blood examinations, the ratio of metabolic syndrome and HCC, and pathological findings in liver biopsy. The ratio of PTPRD rs35929428 GA was significantly increased in patients with higher Fib-4 index Chr/Position, the chromosome and position; Effect Freq control, frequency of the effect allele in controls; Effect Freq NAFLD, frequency of the effect allele in NAFLD; NAFLD, non-alcoholic fatty liver disease.
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PTPRD genes in the development of NAFLD than 1.45 (Fig. 2a) , suggesting that PTPRD rs35929428 GA may be involved in the pathogenesis of fibrosis because Fib-4 index is deeply associated with liver fibrosis. 15 On the other hand, pathological findings failed to show a relation between the stage of hepatic fibrosis assessed by liver biopsy and PTPRD rs35929428 GG and GA patients (Fig. 2b) . Next, we evaluated the relationship between PTPRD rs35929428 and the degree of hepatic fat accumulation. Representative pathological findings are shown in Figure 2c ,d. Mild steatosis was seen in the liver in a PTPRD rs35929428 GG patient (Fig. 2c) , while severe steatosis was observed in PTPRD rs35929428 GA (Fig. 2d) . The analysis of fat accumulation in 29 patients who received liver biopsy demonstrated that the degree of fat droplets was significantly higher in PTPRD rs35929428 GA patients than in PTPRD rs35929428 GG patients (Fig. 2e) , suggesting that PTPRD rs35929428 GA may associate with hepatic lipid accumulation.
The expression of PTPRD in the liver of non-alcoholic fatty liver disease. It was previously reported that PTPases including PTPRD were mainly expressed in the brain, heart, kidney, and placenta. 21 Because little is, however, known whether PTPRD is expressed in the liver, we next analyzed by immunohistochemistry the expression of PTPRD protein in the liver of 15 and 11 NAFLD patients with PTPRD rs35929428 GG and PTPRD rs35929428 GA, respectively. Immunohistochemistry revealed PTPRD protein expression in the cytosol and nucleus of hepatocytes in all patients (Fig. 3a,b) , indicating for the first time that PTPRD is expressed in the hepatocytes. However, the numbers of PTPRD positive cells were not significant in patients with PTPRD rs35929428 GG and PTPRD rs35929428 GA (Fig. 3c) .
The function of PTPRD R995C encoded by PTPRD rs35929428. PTPRD is a transmembrane protein that dephosphorylates STAT3 at tyrosine 705. 22 We evaluated whether PTPRD R995C, which is encoded by PTPRD rs35929428, affected the pSTAT3 in hepatocytes. As immunohistochemistry indicated that PTPRD protein is expressed in hepatocytes, γGTP, γ-glutamyltransferase; Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLp, dyslipidemia; DM, diabetes mellitus; FBS, fasting blood sugar; HCC, hepatocellular carcinoma; HT, hypertension; Plt, platelet count; T-Cho, total cholesterol. Figure 1 Genetic variants of PTPRD rs35929428 in non-alcoholic fatty liver disease (NAFLD). The ratio of PTPRD rs35929428 GA (GA) was significantly higher in NAFLD patients than in healthy volunteers (28.3% vs 7.3%, P = 0.015, odds ratio [OR] = 5.00, 95% confidence interval: 1.33-18.70). , GG; , GA. GG, PTPRD rs35929428 GG.
in vitro study was performed in Huh7 cells. Firstly, we confirmed that Huh7 cells had PTPRD rs35929428 GG type. IL-6 significantly accelerated the pSTAT3 (Tyr 705) in Huh7 cells transfected with wild-type PTPRD, while this acceleration in the pSTAT3 (Tyr 705) was not reproduced in cells transfected with PTPRD R995C (Fig. 4a,b) , suggesting that PTPRD R995C, which is encoded by PTPRD rs35929428, is capable of enhancing the ability of dephosphorylation of STAT3, thereby speculating that PTPRD R995C may play a role in functions related to STAT3 signaling in the liver. As in vitro study demonstrated that PTPRD R995C encoded by PTPRD rs35929428 had gained function of dephosphorylation of STAT3 (Tyr 705) in hepatocytes, next we evaluated by immunohistochemistry the status of pSTAT3 (Tyr 705) in the liver tissue of 16 and 9 NAFLD patients with PTPRD rs35929428 GG and PTPRD rs35929428 GA, respectively. Representative immunohistochemistry revealed that pSTAT3 (Tyr 705) was strongly positive in nuclei of hepatocytes in patients with PTPRD rs35929428 GG (Fig. 4c) when compared with those with PTPRD rs35929428 GA (Fig. 4d) . The numbers of pSTAT3 (Tyr 705) positive cells were significantly decreased in patients with PTPRD rs35929428 GA in comparison with those with PTPRD rs35929428 GG (Fig. 4e) , supporting the results of in vitro analysis. Representative liver biopsy specimens stained with hematoxylin and eosin in patient with PTPRD rs35929428 GG (GG) and PTPRD rs35929428 GA. (e) The degree of fat droplets was shown in PTPRD rs35929428 GA and PTPRD rs35929428 GG patients (the degree of fat droplets: 0, <5%; 1, <10%; 2, <34%; 3, <67%; and 4, >67%). (NS, not significant; *P < 0.05).
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Discussion
In the present study, we identified PTPRD rs35929428 GA as a novel SNP of Japanese NAFLD, which potentially leads to a protein dysfunction. As the prevalence of PTPRD rs35929428 GG, GA, and AA has been reported 81.7%, 13.5%, and 4.8%, respectively, in Japan (http://www.internationalgenome.org/), it may be reasonable why PTPRD rs35929428 AA patients had not been included in our study. There was no association between PNPLA3 rs738409 and NAFLD patients in the present study. According to previous publications, PNPLA3 rs738409 has been considered to be strongly associated with NAFLD. Very recently, Kawaguchi et al. have demonstrated that PNPLA3 rs738409 was strongly associated with Matteoni type 4 NAFLD patients in the analysis of more than 500 NAFLD patients in Japan. 12 Because the present study analyzed a relatively small number of patients with Matteoni type 4, we would conclude that PNPLA3 rs738409 is not to be identified as a candidate gene.
We next examined whether the novel SNP, PTPRD rs35929428 GA, may be related to the pathophysiology of NAFLD. Fat accumulation detected in liver biopsy specimens revealed that a higher steatosis was observed in the PTPRD rs35929428 GA patients than PTPRD rs35929428 GG patients, suggesting that PTPRD rs35929428 GA was associated with the lipid accumulation in the liver in NAFLD patients. Furthermore, in our study, the ratio of Fib-4 index >1.45 for advanced hepatic fibrosis 15 was significantly higher in PTPRD rs35929428 GA, indicating that PTPRD rs35929428 GA may also play a role in the process of liver fibrosis in NAFLD. Because hepatic fat accumulation and hepatic fibrosis are considered to be the main pathological changes in NASH, 23 PTPRD rs35929428 GA might be specifically involved in the development of NASH.
The main function of PTPRD is dephosphorylation of STAT3 (Tyr 705). 22 STAT3 plays a key role in the regulation of hepatic lipid accumulation, inflammation, regeneration, and fibrosis. 24, 25 These findings led us to speculate that the STAT3 signaling may mediate the pathophysiological roles, that is, steatosis and fibrosis, in NAFLD patients with PTPRD rs35929428 GA. For the aforementioned speculation to be addressed, the pSTAT3 in cultured hepatic cells, Huh7, was examined. Firstly, we confirmed that Huh7 cells have PTPRD rs35929428 GG type and then PTPRD R995C-encoded PTPRD rs35929428 GA was transfected. Because STAT3 signaling is activated by various cytokines such as IL-6, we stimulated pSTAT3 with IL-6. In vitro study demonstrated that cell transfected with PTPRD R995C, which is encoded by PTPRD rs35929428 GA, was not capable of inducing the pSTAT3 (Tyr 705) by IL-6, suggesting that PTPRD R995C had gained a function as regards dephosphorylation of STAT3 (Tyr 705). In other words, PTPRD R995C may enhance the activity of dephosphorylation of STAT3, followed by inhibiting the pSTAT3. The in vitro findings may be supported by the results obtained from liver biopsy specimens because pSTAT3 was PTPRD genes in the development of NAFLD S Nakajima et al.
deeply suppressed in PTPRD rs35929428 GA. It is therefore speculated that the lowered pSTAT3 in hepatocytes in NAFLD patients with PTPRD rs35929428 GA may be involved in the hepatic steatosis and fibrosis, the main pathological characteristics of NAFLD including NASH, because STAT3 is deeply involved in the process of hepatic lipid accumulation and fibrosis as described earlier. 24, 25 PTPRD rs35929428 GA was associated with higher Fib-4 index. On the other hand, there was no relation between the degree of liver fibrosis assessed by liver biopsy and PTPRD genotype. Because paired liver biopsies demonstrated significant sampling variability in patients with NASH, 26 a lack of paired sampling might lead to no association. We would raise an additional possibility of a relatively small number of samples in the present study. Based upon these findings, further studies in a large number of the subjects are needed to further clarify whether PTPRD rs35929428 is associated with the liver fibrosis.
In conclusion, the present study revealed the novel SNP PTPRD rs35929428 for Japanese NAFLD. PTPRD rs35929428 was associated with higher Fib-4 index and steatosis. The mechanisms may be explained as follows. PTPRD R995C, which was encoded PTPRD rs35929428, attenuated the pSTAT3 (Tyr 705) in the liver, thereby enhancing hepatic fibrosis and steatosis and leading to the development of NAFLD including NASH.
